Thr1462
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr1462  -  TSC2 (human)

Site Information
GLRPRGytISDsAPs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448546
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 1 ) , immunoprecipitation ( 80 ) , mass spectrometry ( 5 , 7 , 9 , 10 , 12 , 13 , 14 , 16 , 19 , 20 , 22 , 23 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 64 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 74 , 80 ) , mass spectrometry (in vitro) ( 4 ) , mutation of modification site ( 4 , 75 , 77 , 79 , 82 ) , phospho-antibody ( 1 , 2 , 3 , 6 , 8 , 11 , 21 , 24 , 25 , 26 , 63 , 73 , 75 , 76 , 78 , 79 , 81 , 82 ) , western blotting ( 1 , 2 , 3 , 6 , 8 , 11 , 21 , 24 , 25 , 26 , 63 , 73 , 75 , 76 , 78 , 79 , 81 )
Disease tissue studied:
bone cancer ( 63 , 81 ) , brain cancer ( 63 ) , glioblastoma ( 63 ) , glioma ( 63 ) , breast cancer ( 4 , 10 , 11 , 21 , 26 , 63 , 75 , 79 ) , breast ductal carcinoma ( 4 , 10 ) , HER2 positive breast cancer ( 5 ) , luminal A breast cancer ( 5 ) , luminal B breast cancer ( 5 ) , breast cancer, surrounding tissue ( 5 ) , breast cancer, triple negative ( 5 , 10 ) , colorectal cancer ( 6 , 26 ) , colorectal carcinoma ( 6 , 26 ) , gastric cancer ( 27 , 28 , 29 , 30 , 31 , 32 , 33 , 40 , 41 , 44 , 45 , 57 , 58 ) , gastric carcinoma ( 27 , 28 , 29 , 30 , 31 , 32 , 33 , 40 , 41 , 44 , 45 , 57 , 58 ) , leukemia ( 38 ) , chronic myelogenous leukemia ( 38 ) , lung cancer ( 2 , 13 , 14 , 34 , 35 , 36 , 37 , 39 , 42 , 43 , 46 , 47 , 48 , 49 , 50 , 52 , 54 , 55 , 56 , 59 , 63 , 64 , 75 , 76 ) , non-small cell lung cancer ( 2 , 14 , 34 , 35 , 36 , 37 , 39 , 42 , 43 , 46 , 47 , 48 , 49 , 50 , 52 , 54 , 55 , 56 , 59 , 75 , 76 ) , non-small cell lung adenocarcinoma ( 2 , 13 , 14 , 36 , 37 , 39 , 46 , 47 , 48 , 49 , 50 , 59 ) , non-small cell large cell lung carcinoma ( 2 , 14 ) , non-small cell squamous cell lung carcinoma ( 13 , 36 , 37 , 39 , 59 , 64 ) , neuroblastoma ( 25 ) , ovarian cancer ( 26 ) , pancreatic ductal adenocarcinoma ( 12 ) , prostate cancer ( 3 , 26 ) , melanoma skin cancer ( 7 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 78 ) , 'pancreatic, ductal'-pancreas ( 12 ) , 'stem, embryonic' ( 66 ) , 293 (epithelial) [Akt1 (human)] ( 82 ) , 293 (epithelial) [TSC1 (human)] ( 80 ) , 293 (epithelial) [TSC2 (human)] ( 80 , 82 ) , 293 (epithelial) ( 11 , 51 , 63 ) , 293E (epithelial) ( 81 ) , A549 (pulmonary) ( 2 , 63 ) , breast ( 5 , 10 ) , BT-474 (breast cell) ( 75 ) , C4-2 (prostate cell) ( 3 ) , C4-2B (prostate cell) ( 3 ) , Caco-2 (intestinal) ( 6 ) , HCC15 (pulmonary) ( 13 ) , HCC78 (pulmonary) ( 14 ) , HCT116 (intestinal) ( 6 ) , HEK293T (epithelial) ( 4 , 75 ) , HeLa (cervical) ( 4 , 9 , 60 , 61 , 77 ) , Hs 578T (breast cell) ( 75 ) , HT-29 (intestinal) ( 26 ) , JIMT-1 (breast cell) ( 4 ) , Jurkat (T lymphocyte) ( 19 , 20 , 22 , 23 , 53 , 62 , 71 , 74 ) , K562 (erythroid) ( 16 , 38 ) , LNCaP (prostate cell) ( 3 ) , LOU-NH91 (squamous) ( 13 ) , lung ( 13 , 14 , 52 , 54 , 55 , 56 ) , lymphocyte-blood ( 1 ) , MCF-10A (breast cell) ( 11 , 26 ) , MCF-7 (breast cell) ( 11 , 63 , 75 , 79 ) , MDA-MB-231 (breast cell) ( 21 , 26 , 75 ) , MEF (fibroblast) ( 21 , 24 ) , MKN-45 (gastric) ( 27 , 28 , 29 , 30 , 31 , 32 , 33 , 40 , 41 , 44 , 45 , 57 , 58 ) , NCI-H157 (pulmonary) ( 75 ) , NCI-H1703 (squamous) ( 13 , 36 , 37 , 39 , 59 , 64 , 67 , 68 , 69 , 70 , 72 ) , NCI-H1781 (pulmonary) ( 14 ) , NCI-H1975 (pulmonary) ( 2 ) , NCI-H2073 (pulmonary) ( 13 ) , NCI-H2228 (pulmonary) ( 14 ) , NCI-H2342 (pulmonary) ( 13 ) , NCI-H3122 (pulmonary) ( 14 ) , NCI-H3255 (pulmonary) ( 34 , 35 , 42 , 43 ) , NCI-H441 (pulmonary) ( 46 , 47 , 48 , 49 , 50 ) , NCI-H460 (pulmonary) ( 2 ) , NCI-H661 (pulmonary) ( 14 ) , PC3 (prostate cell) ( 26 ) , RKO (intestinal) ( 6 ) , SH-SY5Y (neural crest) ( 25 ) , SKBr3 (breast cell) ( 75 ) , SKOV-3 (ovarian) ( 26 ) , SW480 (intestinal) ( 6 ) , SW620 (intestinal) ( 6 ) , U2OS (bone cell) [GR (human)] ( 81 ) , U2OS (bone cell) ( 63 ) , U87MG (glial) ( 63 ) , WM239A (melanocyte) ( 7 ) , WM793 ( 26 ) , ZR-75-1 (breast cell) ( 75 )

Upstream Regulation
Regulatory protein:
Akt1 (human) ( 73 , 75 ) , Akt2 (human) ( 75 ) , Akt3 (human) ( 75 ) , p16-INK4A (human) ( 8 ) , PHLPP (human) ( 75 ) , PHLPP2 (human) ( 75 ) , PIK3CA (human) ( 26 ) , PINK1 (human) ( 25 ) , PKD1 (human) ( 65 ) , RRas (human) ( 26 )
Putative in vivo kinases:
Akt1 (human) ( 80 , 82 ) , SGK1 (human) ( 4 )
Kinases, in vitro:
Akt1 (human) ( 82 ) , SGK1 (human) ( 4 )
Treatments:
4-HT ( 73 ) , AG1478 ( 25 ) , Akt_inhibitor_VIII ( 25 ) , AZD8055 ( 63 ) , calyculin_A ( 26 ) , dasatinib ( 26 ) , EGF ( 21 , 25 ) , ephrin_A1 ( 26 ) , estradiol ( 79 ) , ethanol ( 26 ) , exercise ( 78 ) , IGF-1 ( 79 ) , imatinib ( 26 , 64 ) , insulin ( 80 , 81 ) , LY294002 ( 26 ) , okadaic_acid ( 26 ) , PD98059 ( 26 ) , pemetrexed ( 2 ) , phorbol_ester ( 80 ) , PI-103 ( 25 ) , PP2 ( 26 ) , rapamycin ( 26 ) , resveratrol ( 1 ) , rosiglitazone ( 76 ) , salinomycin ( 3 ) , SB202190 ( 6 ) , sildenafil ( 2 ) , siRNA ( 21 , 75 ) , tamoxifen ( 73 ) , tautomycin ( 26 ) , U0126 ( 21 ) , wortmannin ( 25 )

Downstream Regulation
Effects of modification on TSC2:
activity, inhibited ( 4 , 80 ) , phosphorylation ( 77 )
Effects of modification on biological processes:
apoptosis, inhibited ( 77 ) , transcription, altered ( 77 )

Disease / Diagnostics Relevance
Relevant diseases:
tuberous sclerosis ( 82 )

References 

1

Craveiro M, et al. (2017) Resveratrol stimulates the metabolic reprogramming of human CD4+ T cells to enhance effector function. Sci Signal 10
29042482   Curated Info

2

Booth L, et al. (2017) PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget 8, 1449-1468
27903966   Curated Info

3

Mirkheshti N, et al. (2016) Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer. Oncotarget 7, 62240-62254
27557496   Curated Info

4

Castel P, et al. (2016) PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Cancer Cell 30, 229-42
27451907   Curated Info

5

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

6

Zhang Y, et al. (2015) PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. EBioMedicine 2, 1944-56
26844273   Curated Info

7

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

8

Damsky W, et al. (2015) mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell 27, 41-56
25584893   Curated Info

9

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

10

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

11

Puustinen P, et al. (2014) CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. J Cell Biol 204, 713-27
24590173   Curated Info

12

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

13

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

14

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

15

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

16

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

17

Gulen MF, et al. (2012) Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity 37, 800-12
23142783   Curated Info

18

Rho SB, et al. (2012) Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cell Signal 24, 131-9
21893193   Curated Info

19

Mulhern D (2011) CST Curation Set: 13261; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: ATM/ATR substrate (s/t)QG Cat#: 6939
Curated Info

20

Mulhern D (2011) CST Curation Set: 13106; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

21

Lu Y, et al. (2011) Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 30, 4567-77
21666717   Curated Info

22

Mulhern D (2011) CST Curation Set: 12686; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

23

Guo A (2011) CST Curation Set: 12074; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

24

Xie X, et al. (2011) IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci U S A 108, 6474-9
21464307   Curated Info

25

Murata H, et al. (2011) A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. J Biol Chem 286, 7182-9
21177249   Curated Info

26

Yang NY, et al. (2011) Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cell Signal 23, 201-12
20837138   Curated Info

27

Moritz A (2010) CST Curation Set: 10611; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

28

Moritz A (2010) CST Curation Set: 10617; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

29

Moritz A (2010) CST Curation Set: 10616; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

30

Moritz A (2010) CST Curation Set: 10609; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

31

Moritz A (2010) CST Curation Set: 10613; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

32

Moritz A (2010) CST Curation Set: 10608; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

33

Moritz A (2010) CST Curation Set: 10612; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

34

Moritz A (2010) CST Curation Set: 10597; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

35

Moritz A (2010) CST Curation Set: 10598; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

36

Moritz A (2010) CST Curation Set: 10595; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

37

Moritz A (2010) CST Curation Set: 10596; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

38

Beausoleil S (2010) CST Curation Set: 10279; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

39

Moritz A (2010) CST Curation Set: 10240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

40

Moritz A (2010) CST Curation Set: 10237; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

41

Moritz A (2010) CST Curation Set: 10234; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

42

Moritz A (2010) CST Curation Set: 10241; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

43

Moritz A (2010) CST Curation Set: 10242; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

44

Moritz A (2010) CST Curation Set: 10236; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

45

Moritz A (2010) CST Curation Set: 10231; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

46

Moritz A (2010) CST Curation Set: 9985; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

47

Moritz A (2010) CST Curation Set: 9984; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

48

Moritz A (2010) CST Curation Set: 9986; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

49

Moritz A (2010) CST Curation Set: 9980; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

50

Moritz A (2010) CST Curation Set: 9987; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

51

Guo A (2010) CST Curation Set: 6270; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

52

Rikova K (2010) CST Curation Set: 9760; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

53

Rikova K (2010) CST Curation Set: 9774; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

54

Rikova K (2010) CST Curation Set: 9772; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

55

Rikova K (2010) CST Curation Set: 9752; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

56

Rikova K (2010) CST Curation Set: 9767; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

57

Moritz A (2010) CST Curation Set: 9279; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

58

Moritz A (2010) CST Curation Set: 9234; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

59

Moritz A (2010) CST Curation Set: 9240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

60

Moritz A (2010) CST Curation Set: 9237; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

61

Moritz A (2010) CST Curation Set: 9243; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

62

Moritz A (2010) CST Curation Set: 8838; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

63

Chresta CM, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70, 288-98
20028854   Curated Info

64

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

65

Dere R, Wilson PD, Sandford RN, Walker CL (2010) Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR. PLoS One 5, e9239
20169078   Curated Info

66

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

67

Moritz A (2009) CST Curation Set: 5890; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

68

Moritz A (2009) CST Curation Set: 5893; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

69

Moritz A (2009) CST Curation Set: 5895; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

70

Moritz A (2009) CST Curation Set: 5884; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

71

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

72

Moritz A (2008) CST Curation Set: 5443; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

73

Vojtechová M, et al. (2008) Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells. Neoplasia 10, 99-107
18283331   Curated Info

74

Possemato A (2008) CST Curation Set: 3661; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:pSXXXpS
Curated Info

75

Brognard J, Sierecki E, Gao T, Newton AC (2007) PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25, 917-31
17386267   Curated Info

76

Han S, Zheng Y, Roman J (2007) Rosiglitazone, an Agonist of PPARgamma, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2. PPAR Res 2007, 29632
17597835   Curated Info

77

Freilinger A, et al. (2006) Tuberin activates the proapoptotic molecule BAD. Oncogene 25, 6467-79
16702951   Curated Info

78

Dreyer HC, et al. (2006) Resistance exercise increases AMPK activity and reduces 4E-BP1 phosphorylation and protein synthesis in human skeletal muscle. J Physiol 576, 613-24
16873412   Curated Info

79

Yu J, Henske EP (2006) Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain. Cancer Res 66, 9461-6
17018601   Curated Info

80

Roux PP, et al. (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A 101, 13489-94
15342917   Curated Info

81

Tee AR, et al. (2002) Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 99, 13571-6
12271141   Curated Info

82

Manning BD, et al. (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10, 151-62
12150915   Curated Info